A Phase 1 study of Oxaloacetate in Myasthenia Gravis

Withdrawn Phase 1 NCT04965987

Study Description

Investigating the Effects of Oxaloacetate in Patients with Myasthenia Gravis

Study Details

Registry ID:: NCT04965987
Conditions:: Myasthenia Gravis
Phase:: Phase 1
Start Date:: August 1, 2025
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (1 site)

University of Kansas Medical Center
Kansas City, KansasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →